Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma

Philipp M. Kazmierczak, Neal C. Burton, Georg Keinrath, Heidrun Hirner-Eppeneder, Moritz J. Schneider, Ralf S. Eschbach, Maurice Heimer, Olga Solyanik, Andrei Todica, Maximilian F. Reiser, Jens Ricke, Maurice Heimer, Olga Solyanik, Andrei Todica, Maximilian F. Reiser, Jens Ricke, Clemens C. Cyran

1 Department of Radiology, Laboratory for Experimental Radiology, University Hospital, LMU Munich, München, Germany, 2 iThera Medical GmbH, München, Germany, 3 Comprehensive Pneumology Center, German Center for Lung Research, Munich, Germany, 4 Department of Nuclear Medicine, University Hospital, LMU Munich, München, Germany

* philipp.kazmierczak@med.lmu.de

Abstract

Purpose
To investigate αvβ3-integrin-targeted optoacoustic imaging and MRI for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma.

Materials and methods
Human BRAF V600E-positive melanoma xenograft (A375)-bearing Balb/c nude mice (n = 10) were imaged before (day 0) and after (day 7) a BRAF/MEK inhibitor combination therapy (encorafenib, 1.3 mg/kg/d; binimetinib, 0.6 mg/kg/d, n = 5) or placebo (n = 5), respectively. Optoacoustic imaging was performed on a preclinical system unenhanced and 5 h after i. v. injection of an αvβ3-integrin-targeted fluorescent probe. The αvβ3-integrin-specific tumor signal was derived by spectral unmixing. For morphology-based tumor response assessments, T2w MRI data sets were acquired on a clinical 3 Tesla scanner. The imaging results were validated by multiparametric immunohistochemistry (β3-integrin expression, CD31 -microvascular density, Ki-67 –proliferation).

Results
The αvβ3-integrin-specific tumor signal was significantly reduced under therapy, showing a unidirectional decline in all animals (from 7.98±2.22 to 1.67±1.30; p = 0.043). No significant signal change was observed in the control group (from 6.60±6.51 to 3.67±1.93; p = 0.500). Immunohistochemistry revealed a significantly lower integrin expression (β3: 0.20±0.02 vs. 0.39±0.05; p = 0.008) and microvascular density (CD31: 119±15 vs. 292±49; p = 0.008) in the therapy group. Tumor volumes increased with no significant intergroup difference (therapy: +107±42 mm³; control +112±44mm³, p = 0.841). In vivo blocking studies with αvβ3-integrin antagonist cilengitide confirmed the target specificity of the fluorescent probe.
Conclusions

αvβ3-integrin-targeted optoacoustic imaging allowed for the early non-invasive monitoring of a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma, adding molecular information on tumor receptor status to morphology-based tumor response criteria.

Introduction

Overactivation of the mitogen-activated protein kinase (MAPK) signal pathway by b-rapidly accelerated fibrosarcoma (BRAF) gene mutations V600E/K leads to uncontrolled proliferation of human cells and is a central mechanism of oncogenesis in melanoma [1, 2]. Selective BRAF inhibitors (BRAFi) disrupt this oncogenic stimulus and demonstrate high initial tumor response rates in metastatic melanoma [3, 4]. However, intrinsic or acquired BRAFi resistance limits long-term tumor response to BRAFi monotherapies [5]. One major mechanism of acquired BRAFi resistance is MAPK pathway activation by the mitogen-activated extracellular signal-regulated kinase (MEK), which may be overcome by selective MEK inhibitors (MEKi) [6]. Dual targeting of the MAPK signal pathway by a BRAFi/MEKi combination therapy demonstrated significantly improved overall and progression-free survival in patients with advanced BRAF-mutant melanoma compared to BRAFi monotherapy [7]. BRAFi/MEKi combination therapy is a first-line option in patients with BRAF-mutant metastatic melanoma (National Comprehensive Cancer Network Guidelines Version 1.2017, www.nccn.org).

Targeted therapies yield only subtle effects on tumor size and therefore limit the applicability of morphology-based criteria of tumor response [8]. As functional and molecular imaging allow for the non-invasive characterization of the tumor microenvironment beyond morphology, they bear the potential to provide novel, complementary imaging biomarkers of tumor response [9]. Functional and molecular imaging biomarkers may be better suited than size-based response criteria in correlation with clinical endpoints such as early therapy response or progression-free survival [10, 11].

αvβ3-integrin is a transmembrane protein overexpressed on angiogenic endothelium and tumor cells [12]. Depending on the investigated tumor model, αvβ3-integrin is a target structure for the non-invasive in vivo investigation of tumor angiogenesis and tumor cell populations [13]. In melanoma, αvβ3-integrin plays an important role in neoangiogenesis and tumor progression from the non-invasive, radial to the invasive, vertical growth phase [14, 15]. Herzog et al. demonstrated the applicability of optoacoustic imaging with a targeted fluorescent probe for the characterization of αvβ3-integrin receptor status in human tumor xenografts in vivo [16].

The purpose of this experimental proof-of-principle study was to investigate αvβ3-integrin-targeted optoacoustic imaging and MRI for the non-invasive in vivo monitoring of a BRAFi/MEKi combination therapy in a murine xenograft model of human melanoma, validated by multiparametric ex vivo immunohistochemistry. We hypothesized that the αvβ3-integrin-specific optoacoustic signal would be significantly reduced under targeted therapy, delivering a surrogate of suppressed tumor αvβ3-integrin expression over the treatment course and adding quantitative, dual time point molecular information on the tumor microenvironment to morphology-based assessments of tumor response.

Materials and methods

The study was approved by the Government of Upper Bavaria Committee of Animal Research (Gz. ROB-55.2-2532.Vet_02-15-204) and conducted in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals. All applicable institutional and/or national guidelines for the care and use of animals were followed. Every effort was taken to reduce animal suffering. We kept the mice in individually ventilated cages (n = 4 mice per cage, relative air humidity 65% at n = 18 room air changes/h, temperature 26˚C, light-dark-cycle 12 h), nourished with water and small animal nutrition. Nest boxes and nestles ensured environmental enrichment. Daily animal monitoring including weighing and tumor growth measurement was conducted. Abnormal inactivity was considered an indicator of pain and was treated by analgesia (0.5 mg/kg buprenorphine s. c.). The experiments were performed under isoflurane anesthesia (2.5% in 1.0 L of 100% O₂ per min for induction and 2.5% in 1.0 L of 100% O₂ per min for maintenance). Humane endpoints leading to euthanization were: maximum tumor diameter > 1.5 cm, tumor exulceration, weight loss > 15%, apathy, defense reaction when palpating tumors, respiratory problems, paresis, non-physiological body posture.

Tumor model and experimental setup
Human BRAF V600E-positive melanoma cells (A375; ATCC CRL-1619, CLS Cell Lines Service GmbH, Eppelheim, Germany) were diluted in 0.1 mL of a 1:1 mixture of phosphate-buffered saline (PBS pH 7.4; GIBCO Life Technologies, Darmstadt, Germany) and Matrigel (BD Biosciences, San Jose, CA). The resulting mixture was subcutaneously injected into the left abdominal flank of n = 10 Balb/c nude mice (Charles River, Sulzfeld, Germany; 3 x 10⁶ cells/mouse). After reaching a tumor diameter of 0.5 cm, animals were randomized to either the therapy (n = 5) or the control group (n = 5). αvβ3-integrin-targeted optoacoustic imaging and magnetic resonance imaging (MRI) were performed on day 0 (baseline) and day 7 (follow-up). After optoacoustic imaging, animals were transferred to the MRI suite. T2-weighted (T2w) MRI was performed for anatomic colocalization and morphologic tumor response assessments (MR volumetry). Between baseline and follow-up imaging, animals were treated daily for one week with either BRAFi/MEKi combination therapy (BRAFi: encorafenib, 1.3 mg/kg/d; MEKi: binimetinib, 0.6 mg/kg/d; both Array BioPharma Inc., Boulder, CO) or a volume-equivalent placebo solution (1% carboxymethyl cellulose and 0.5% Tween-80 in ddH₂O). After follow-up imaging, animals were sacrificed and the explanted tumors were fixed in formalin. Multiparametric immunohistochemical workup included β3-integrin expression, microvascular density (CD31), and tumor cell proliferation (Ki-67).

Optoacoustic imaging
Optoacoustic imaging was performed on a dedicated small animal imaging system (inVision 256-TF, iThera Medical GmbH, Munich, Germany) [17]. Briefly, a tunable optical parametric oscillator pumped by a neodymium-doped yttrium aluminum garnet laser provided excitation pulses with a duration of 9 ns at wavelengths from 680 nm to 980 nm at a repetition rate of 10 Hz with a wavelength tuning speed of 10 ms and a peak pulse energy of 100 mJ at 730 nm. Ten arms of a fiber bundle provided even illumination of a ring-shaped light strip of approximately 8 mm width. For ultrasound detection, 256 toroidally focused ultrasound transducers with a center frequency of 5 MHz (60% bandwidth), organized in a concave array of 270° angular coverage and a radius of curvature of 4 cm, were used. Animals were scanned at the following n = 11 wavelengths: 700 nm, 730 nm, 740 nm, 750 nm, 760 nm, 770 nm, 780 nm, 790 nm, 800 nm, 850 nm, 900 nm. N = 10 pulses were averaged per wavelength, giving a temporal resolution per multispectral cycle of 11 s. After animals were placed into the system, the positions of the rostral and caudal ends of the tumor were identified to mark the start and stop locations of the scan (typically approximately 1 cm). A step size of 0.5 mm was used to scan through the tumor. Animals were scanned before and 5 h after i. v. injection of a commercially available
αβ3-integrin-targeted fluorescent probe (IntegriSense 750, 4 nmol; Perkin Elmer, Waltham, MA). The data was reconstructed with ViewMSOT (iThera Medical GmbH, Munich, Germany) using the back projection method. Reconstructed baseline images were used to model the optoacoustic profile of the tumor using an adaptive match filter spectral unmixing algorithm [18]. These models were then applied on a per mouse basis to the 5 h scans, where deviations from the model consistent with the absorption spectrum of the αβ3-integrin-targeted fluorescent probe were revealed. Regions of interest (ROI) were manually drawn on single wavelength images to identify the tumor, and the average spectrally unmixed αβ3-integrin-targeted optoacoustic signal was quantified (arbitrary units, a. u.). Single wavelength background images were displayed in greyscale with a Frangi filter applied to enhance anatomical detail [19].

MRI

MRI was performed on a clinical 3 Tesla scanner (MAGNETOM Skyra, Siemens Healthineers, Erlangen, Germany). Animals were scanned head-first in prone position. T2w data sets were acquired using a 2D Turbo Spin Echo sequence (TR = 5470 ms, TE = 91 ms, in-plane resolution 0.3 x 0.3 mm, matrix size 192 x 192, slice thickness 1.5 mm). MR volumetry was conducted on an external workstation using dedicated post-processing software written in-house (PMI; Platform for Research in Medical Imaging, version 0.4) [20].

Planar whole-animal cryofluorescence imaging

In order to visualize the biodistribution of the targeted fluorescent probe, planar cryofluorescence images were acquired as described elsewhere [21]. Briefly, a cryostat was retrofitted with a light source, filters, and a camera which enabled acquisition of color images as well as fluorescence images of frozen specimen.

In vivo blocking studies

Competition in vivo blocking studies were performed to confirm the target specificity of the αβ3-integrin-targeted fluorescent probe. For blocking, αβ3-integrin receptor antagonist cilengitide (800 μg; Selleck Chemicals, Houston, TX) was injected i. v. 15 min prior to injection of the αβ3-integrin-targeted fluorescent probe (4 nmol). Optoacoustic imaging and signal quantification were then performed as described above and signal intensities of blocked and unblocked animals were compared accordingly.

Immunohistochemistry

Microscope slides with 3 μm sections from paraffin-embedded tissue were dewaxed and rehydrated following standard procedures (preheating at 60 °C, xylene substitute [Neo-Clear, Merck KgaA, Darmstadt, Germany] graded series of ethanol (100%, 96%, 80% and 70%), followed by double distilled water). After antigen demasking (microwave irradiation at 600 W, 0.1 M citrate buffer pH 6.0) and overnight incubation with the primary antibodies (anti-β3-integrin antibody Abcam ab179473, 1:500, anti-CD31 antibody Abcam ab28364 1:50, anti-Ki-67 antibody SP6 Abcam ab16667 1:100 [all Cambridge, United Kingdom]) at 4 °C, tissue samples were further processed using the EnVision+ System HRP (DAB or AEC) (DAKO Diagnostika, Hamburg, Germany) kit according to the manufacturer’s instructions. Slides were counterstained with Mayer’s Haemalaun (Merck KgaA, Darmstadt, Germany) and covered with Kaiser’s Glycerin Gelatine (Merck KgaA, Darmstadt, Germany). The optical density of β3-integrin expression was measured in ten random fields at 200x magnification using ImageJ.
CD31-positive microvessels and Ki-67-positive nuclei were quantified in ten random high-power fields at 200x magnification.

**Statistical analysis**

Statistical analysis was performed using commercially available statistics software (SPSS 24, IBM Corp., Armonk, NY). The continuous parameters were expressed as means with standard deviations (95% confidence intervals). For intragroup comparisons (follow-up vs. baseline), the Wilcoxon test was applied, while the Mann-Whitney U test was applied for intergroup comparisons. The confirmatory tests (\(\alpha_v\beta_3\)-integrin-specific optoacoustic signal at follow-up vs. baseline; \(\beta_3\)-integrin in the therapy vs. the control group) were compared against Bonferroni-Holm-adjusted \(\alpha\) levels (\(\alpha = 0.05\)). All other tests were compared against \(\alpha = 0.05\) as they were considered exploratory.

**Results**

**Optoacoustic imaging**

The \(\alpha_v\beta_3\)-integrin-specific optoacoustic signal was significantly reduced under therapy, demonstrating a unidirectional decline in all animals (mean signal: from 7.98±2.22 a. u. to 1.67±1.30 a. u.; \(p = 0.043\)). No statistically significant change of the optoacoustic signal was observed in the control group, with a heterogeneous development of individual values (mean signal: from 6.60±6.51 a. u. to 3.67±1.93 a. u.; \(p = 0.500\)). There was no statistically significant difference in baseline optoacoustic signals between the therapy and the control group (mean signal: therapy 7.98±2.22 a. u. vs. control 6.60±6.51 a. u.; \(p = 0.690\)). Individual optoacoustic signal intensities at baseline and follow-up are displayed in Table 1 and Fig 1. Fig 2 shows a single wavelength optoacoustic image for anatomical reference in greyscale and the spectrally unmixed, \(\alpha_v\beta_3\)-integrin-specific signal in fire. Representative color-coded tumor maps of exemplary animals from the therapy and the control group before and after treatment are provided in Fig 3. Competitive blocking studies confirmed the target specificity of the \(\alpha_v\beta_3\)-integrin-targeted fluorescent probe (Fig 4). The \(\alpha_v\beta_3\)-integrin-targeted fluorescent probe

| Animal no. | T/C | Signal\(_{baseline}\) | Signal\(_{follow-Up}\) | Vol\(_{baseline}\) | Vol\(_{follow-Up}\) | ΔVol |
|------------|-----|----------------------|-----------------------|-------------------|---------------------|-----|
| 1          | T   | 10.40                | 1.24                  | 23.5              | 190.7               | 167.7|
| 2          | T   | 9.92                 | 0.78                  | 32.0              | 143.4               | 111.4|
| 3          | T   | 7.82                 | 1.10                  | 51.1              | 144.8               | 93.7 |
| 4          | T   | 5.09                 | 1.26                  | 38.6              | 88.1                | 49.5 |
| 5          | T   | 6.66                 | 3.96                  | 30.0              | 144.2               | 114.2|
| Mean±SD\(^t\) | T   | 7.98±2.22            | 1.67±1.30             | 35±10             | 142±36              | 107±43|
| 6          | C   | 15.30                | 6.60                  | 117.1             | 244.6               | 127.5|
| 7          | C   | 11.80                | 2.67                  | 60.4              | 120.4               | 60.0 |
| 8          | C   | 3.15                 | 1.51                  | 57.4              | 205.7               | 148.3|
| 9          | C   | 1.14                 | 3.27                  | 43.5              | 197.3               | 153.8|
| 10         | C   | 1.60                 | 4.39                  | 29.4              | 101.8               | 72.4 |
| Mean±SD\(^t\) | C   | 6.60±6.51            | 3.67±1.93             | 62±33             | 174±54              | 112±39|

\(^t\): T = therapy group; C = control group
\(^t\): SD = standard deviation

https://doi.org/10.1371/journal.pone.0204930.t001

("Fiji" version, www.fiji.sc).
demonstrated tumor-specific binding in all animals with a representative biodistribution of the fluorescent probe shown in Fig 5.

**MRI**

Tumor volumes increased in both the therapy and the control group with no statistically significant intergroup difference ($\Delta V_{\text{Vol}_{\text{Therapy}}} +107\pm42 \text{ mm}^3$ vs. $\Delta V_{\text{Vol}_{\text{Control}}} +112\pm44 \text{ mm}^3$; $p = 0.841$). There was no difference in baseline tumor volumes between the therapy and the control group ($V_{\text{Vol}_{\text{TherapyBL}}} 35\pm10 \text{ mm}^3$ vs. $V_{\text{Vol}_{\text{ControlBL}}} 62\pm33 \text{ mm}^3$; $p = 0.151$). Individual tumor volumes at baseline and follow-up are provided in Table 1 and Fig 6. T2w images of a representative animal from the control group at baseline and follow-up are provided in Fig 7.

**Immunohistochemistry**

In line with the optoacoustic imaging results, $\beta_3$-integrin expression was statistically significantly lower in the therapy group ($\beta_3$: $0.20\pm0.02$ vs. $0.39\pm0.05$; $p = 0.008$). We observed a statistically significantly lower microvascular density in the therapy group compared to the control group ($CD31: 119\pm15$ vs. $292\pm49$; $p = 0.008$). There was a statistically non-significant lower tumor cell proliferation in treated compared to untreated animals ($Ki-67: 3,925\pm1,693$ vs. $5,782\pm1,092$ $p = 0.151$). Individual values for the immunohistochemical parameters are provided in Table 2. Immunohistochemical stainings of representative tumor sections are provided in Fig 8.
Discussion

In the present study, we investigated αvβ3-integrin-targeted optoacoustic imaging and morphologic MRI for the non-invasive in vivo monitoring of a BRAFi/MEKi combination therapy in a murine model of human melanoma. Imaging was validated in and ex vivo: (1) In vivo blocking studies verified the αvβ3-integrin specificity of the targeted fluorescent probe, (2) ex vivo planar whole-animal cryofluorescence imaging confirmed tumor-specific probe binding, and (3) ex vivo immunohistochemistry demonstrated a statistically significant suppression of β3-integrin expression under therapy. In correlation with the ex vivo immunohistochemistry, the αvβ3-integrin-targeted optoacoustic signal was statistically significantly reduced under therapy, while no statistically significant change was observed in the control group. Tumor volumes increased in both the therapy and the control group. This proof-of-principle study demonstrates the feasibility of optoacoustic imaging with a targeted fluorescent probe for the longitudinal, quantitative dual time point monitoring of a molecular cancer therapy in vivo.

Fig 2. Overview of αvβ3-integrin-specific optoacoustic imaging. Balb/c nude mouse. Axial plane. Tumor margins indicated by white dashed line. A: Optoacoustic image (850 nm). B: Spectrally unmixed αvβ3-integrin-specific signal. C: Overlay of A and B. Note the tumor-specific binding of the αvβ3-integrin-targeted fluorescent probe.

https://doi.org/10.1371/journal.pone.0204930.g002

Fig 3. αvβ3-integrin-specific signal before and after treatment of Balb/c nude mice. A: therapy, baseline. B: therapy, follow-up. C: control, baseline. D: control, follow-up. Note the significant decrease in αvβ3-integrin-specific optoacoustic signal following BRAFi/MEKi combination therapy (B vs. A). No significant change in αvβ3-integrin-specific optoacoustic signal is observed in the control group (D vs. C).

https://doi.org/10.1371/journal.pone.0204930.g003
adding complementary molecular information on $\alpha_v\beta_3$-integrin receptor status to morphology-based assessments of tumor response.

Several groups investigated the potential of preclinical optoacoustic imaging with targeted probes for the non-invasive characterization of the tumor microenvironment in vivo [16, 22–25]. $\alpha_v\beta_3$-integrin-targeted fluorescent probes were studied to qualitatively visualize experimental human breast carcinomas and glioblastomas [16, 24]. However, reproducible signal quantifiability is an essential prerequisite for therapy monitoring. Our study adds to the literature as it presents a first approach to quantify the fluorescent signal at different time points under therapy validated by immunohistochemistry, evaluating the potential of optoacoustic imaging.

Fig 4. In vivo blocking experiments. Competitive in vivo blocking studies with $\alpha_v\beta_3$-integrin receptor antagonist cilengitide confirmed the specificity of the targeted fluorescent probe. Note the significant optoacoustic tumor signal increase in unblocked animals (control). No significant change in optoacoustic tumor signal was observed in blocked animals.

https://doi.org/10.1371/journal.pone.0204930.g004

Fig 5. Planar whole-animal cryofluorescence imaging. Balb/c nude mouse. A: macroscopic color image. B: fluorescence image. T: tumor; K: kidneys; I: intestines. The targeted fluorescent probe showed a tumor-specific binding. Analogous to the in vivo optoacoustic images, little background signal is noted in the intestines.

https://doi.org/10.1371/journal.pone.0204930.g005
imaging for therapy monitoring in future clinical trials. Optoacoustic imaging yields high translational potential with a focus on tumors located close to the body surface. Clinical optoacoustic imaging systems were already investigated in melanoma, inflammatory bowel disease, breast cancer, and thyroid cancer [26–29]. Clinical optoacoustic imaging allows for the acquisition of anatomical and functional information on tumors and healthy tissues exploiting intrinsic tissue contrast and visualizing endogenous absorbers (melanin and oxygenated/deoxygenated hemoglobin) [26, 27]. However, in order to generate molecular information such as

![Fig 6. Tumor volumes at baseline and follow-up.](https://doi.org/10.1371/journal.pone.0204930.g006)

Fig 6. Tumor volumes at baseline and follow-up. Solid lines: therapy group. Dashed lines: control group. In both therapy and control group, tumor volumes increased over the treatment course with no significant intergroup difference.

![Fig 7. Morphologic MRI data sets of a representative animal from the control group at baseline and follow-up.](https://doi.org/10.1371/journal.pone.0204930.g007)

Fig 7. Morphologic MRI data sets of a representative animal from the control group at baseline and follow-up. Balb/c nude mouse. A: baseline. B: follow-up. Tumor indicated by red dashed line. Note the tumor volume increase from baseline to follow-up.
tumor receptor status, exogenous absorbers, i.e., targeted probes, are necessary [30]. Despite the promising preclinical results reported in the literature, data on clinical optoacoustic imaging with targeted fluorescent probes are still lacking and data on the use of targeted fluorescent probes in humans are limited. Indocyanine green and methylene blue are two non-targeted near-infrared range fluorochromes approved by the Food and Drug Administration for the use in humans, but these unspecific blood pool agents fail to provide information on tumor-inherent target structures [31]. In clinical studies, targeted fluorescent agents were already investigated for the guidance of surgical and endoscopic procedures [32–34]. For instance, a folate-receptor α-targeted fluorescent probe emitting in the visible spectrum (500 nm) was recently investigated in patients with ovarian or breast cancer to intraoperatively detect additional tumor lesions and to aid the definition of tumor margins [33]. Contrast agents that absorb in near-infrared, which would enable the deepest possible imaging in tissue for optoacoustics, are also available and were applied in clinical studies for optical imaging. For example, bevacizumab-IRDye800CW was used to detect colorectal peritoneal metastases intraoperatively with the use of a fluorescence camera [35]. Optoacoustic imaging could be used for similar applications, though its capability of deeper tissue penetration could potentially offer additional benefits intraoperatively or in non-invasive settings. However, biodistribution and biocompatibility of targeted, near-infrared fluorescence imaging agents in humans remain major issues that need to be addressed before clinical translation. Binding to non-target tissues as well as the enhanced permeability and retention effect may lower the target-to-background signal and therefore limit the applicability for therapy monitoring [31, 36]. For local staging under therapy, subcutaneous injection of the targeted probe analogously to interstitial MR lymphography with consecutive lymphatic transport to the target tumor (melanoma) would be a possible approach to reduce the systemic side effects in humans and may be investigated in future studies.

The role of optoacoustic imaging compared to alternative αβ3-integrin-targeted imaging modalities remains to be defined. Positron emission tomography (PET) with targeted radionuclides as well as MRI using targeted contrast agents also allow for the non-invasive characterization of αβ3-integrin receptor status in vivo [13, 37–39]. Compared to optoacoustic imaging, these modalities are not limited by low tissue penetration depth and are superior with regard
to whole-body tumor staging. However, the lack of ionizing radiation, lower costs compared to PET and MRI, and the availability of clinical imaging devices for bedside use are major advantages of optoacoustic imaging. One potential application of handheld optoacoustic scanners may be the monitoring of superficially-located target lesions, i.e., lymph node metastases, cutaneous metastases, or the primary tumor (if unresectable). This could be performed as part of a multimodality imaging protocol complementary to established imaging modalities such as $^{18}$F-fluorodeoxyglucose-PET/computed tomography or MRI, generating a surrogate of whole-body tumor receptor status under targeted therapy.
Limitations

We acknowledge several limitations of the present study. First, the animal number was small and the results including reproducibility of the quantitative data need to be validated in larger cohorts. However, this can be considered appropriate for the study purpose, which was to provide a first proof-of-principle of quantitative dual time point optoacoustic imaging for therapy monitoring in a small animal model of human melanoma. In addition, Joseph et al. recently provided evidence for the reproducibility and repeatability of quantitative in vivo optoacoustic imaging [40]. Second, the imaging results were validated by single time point immunohistochemistry and the follow-up interval was limited to one week. Additional follow-up intervals for both imaging and immunohistochemistry may reveal deeper insights into the development of αvβ3-integrin expression and the according optoacoustic signal over the therapy course. Third, αvβ3-integrin-targeted imaging may be limited by elevated background signal as αvβ3-integrin is not only expressed by tumors, but also several non-target tissues including the gut and the liver [41]. The localization of the tumor may thus have an effect on ROI selection and signal quantifiability. Nevertheless, the detected αvβ3-integrin-specific optoacoustic signal allowed for a good depiction of the tumor against the background in all animals, which can be attributed to the relatively high αvβ3-integrin expression of the A375 cell line compared to other available melanoma models [42].

Conclusions

In this experimental study, αvβ3-integrin-targeted optoacoustic imaging allowed for the in vivo monitoring of a BRAFi/MEKi combination therapy in a murine model of human melanoma. Our results provide a proof-of-principle of quantitative dual time point optoacoustic imaging for therapy monitoring in vivo.

Author Contributions

Conceptualization: Philipp M. Kazmierczak, Neal C. Burton, Georg Keinrath, Heidrun Hirner-Eppeneder, Clemens C. Cyran.

Data curation: Philipp M. Kazmierczak, Clemens C. Cyran.

Formal analysis: Philipp M. Kazmierczak, Neal C. Burton, Georg Keinrath, Heidrun Hirner-Eppeneder, Moritz J. Schneider, Maurice Heimer, Clemens C. Cyran.

Funding acquisition: Philipp M. Kazmierczak, Heidrun Hirner-Eppeneder, Maximilian F. Reiser, Clemens C. Cyran.

Investigation: Philipp M. Kazmierczak, Georg Keinrath, Heidrun Hirner-Eppeneder, Moritz J. Schneider, Ralf S. Eschbach, Maurice Heimer, Olga Solyanik, Clemens C. Cyran.

Methodology: Philipp M. Kazmierczak, Neal C. Burton, Heidrun Hirner-Eppeneder, Moritz J. Schneider, Clemens C. Cyran.

Project administration: Philipp M. Kazmierczak, Clemens C. Cyran.

Resources: Philipp M. Kazmierczak, Neal C. Burton, Clemens C. Cyran.

Software: Neal C. Burton, Moritz J. Schneider.

Supervision: Philipp M. Kazmierczak, Clemens C. Cyran.

Validation: Philipp M. Kazmierczak, Neal C. Burton, Clemens C. Cyran.
Visualization: Philipp M. Kazmierczak, Neal C. Burton, Georg Keinrath, Heidrun Hirner-Eppeneder, Moritz J. Schneider, Clemens C. Cyran.

Writing – original draft: Philipp M. Kazmierczak, Neal C. Burton, Georg Keinrath, Heidrun Hirner-Eppeneder, Moritz J. Schneider, Ralf S. Eschbach, Clemens C. Cyran.

Writing – review & editing: Philipp M. Kazmierczak, Neal C. Burton, Georg Keinrath, Heidrun Hirner-Eppeneder, Moritz J. Schneider, Ralf S. Eschbach, Maurice Heimer, Olga Solyanik, Andrei Todica, Maximilian F. Reiser, Jens Ricke, Clemens C. Cyran.

References
1. Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, et al. The mitogen-activated protein kinase pathway in melanoma part I—Activation and primary resistance mechanisms to BRAF inhibition. Eur J Cancer. 2017; 73: 85–92. https://doi.org/10.1016/j.ejca.2016.12.016 PMID: 28169847
2. Yadav V, Chen SH, Yue YG, Buchanan S, Beckmann RP, Peng SB. Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. Pharmacol Ther. 2015; 149: 139–49. https://doi.org/10.1016/j.pharmthera.2014.12.003 PMID: 25550229
3. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366: 707–14. https://doi.org/10.1056/NEJMoa112302 PMID: 22139909
4. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer. 2013; 49: 1297–304. https://doi.org/10.1016/j.ejca.2012.11.019 PMID: 23290787
5. Manzano JL, Layos L, Buge C, de Los Llanos Gil M, Vila L, Martinez-Balibrea E, et al. Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med. 2016; 4: 237. https://doi.org/10.21037/atm.2016.06.07 PMID: 27429663
6. da Silveira Nogueira Lima JP, Georgiev a M, Haaland B, de Lima Lopes G. A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma. Cancer Med. 2017.
7. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009; 35: 309–21. https://doi.org/10.1016/j.ctrv.2008.12.001 PMID: 19136215
8. Teng FF, Meng X, Sun XD, Yu JM. New strategy for monitoring targeted therapy: molecular imaging. Int J Nanomedicine. 2013; 8: 3703–13. https://doi.org/10.2147/IJN.S51264 PMID: 24124361
9. Borchmann P, Goergen H, Koe B, Koha L, Greil R, Eichenaier DA, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017.
10. Riedl CC, Pinker K, Ulane GA, Ong LT, Baltzer P, Jochemson MS, et al. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2017; 44: 1428–37. https://doi.org/10.1007/s00259-017-3703-7 PMID: 28462446
11. Gaertner FC, Schwaiger M, Beer AJ. Molecular imaging of αvβ3 expression in cancer patients. Q J Nucl Med Mol Imaging. 2010; 54: 309–26. PMID: 20639816
12. Kazmierczak PM, Todica A, Gildehaus FJ, Hirner-Eppeneder H, Brendel M, Eschbach RS, et al. 68Ga-TRAP-(RG D)3 Hybrid Imaging for the In Vivo Monitoring of αvβ3-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer. PLoS One. 2016; 11: e0168248. https://doi.org/10.1371/journal.pone.0168248 PMID: 27992512
13. Mahabeleshwar GH, Bybosa TV. Angiogenesis in melanoma. Semin Oncol. 2007; 34: 555–65. https://doi.org/10.1053/j.seminoncol.2007.09.009 PMID: 18083379
14. Hsu MY, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, et al. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol. 1998; 153: 1435–42. PMID: 9811334
15. Herzog E, Taruttis A, Bezziere N, Lutich AA, Razansky D, Ntziahristos V. Optical imaging of cancer heterogeneity with multispectral optical tomography. Radiology. 2012; 263: 461–8. https://doi.org/10.1148/radiol.11111646 PMID: 22517960
17. Morscher S, Driessen WH, Claussen J, Burton NC. Semi-quantitative Multispectral Optoacoustic Tomography (MSOT) for volumetric PK imaging of gastric emptying. Photoacoustics. 2014; 2: 103–10. https://doi.org/10.1016/j.poac.2014.06.001 PMID: 25431754

18. Tzoumas S, Deliolanis N, Morscher S, Ntziachristos V. Unmixing Molecular Agents From Absorbing Tissue in Multispectral Optoacoustic Tomography. IEEE Trans Med Imaging. 2014; 33: 48–60. https://doi.org/10.1109/TMI.2013.2279994 PMID: 24001986

19. Wang D, Wang Y, Wang W, Luo D, Chitguppi U, Geng J, et al. Deep tissue photoacoustic computed tomography with a fast and compact laser system. Biomed Opt Express. 2017; 8: 112–23. https://doi.org/10.1364/BOE.8.000112 PMID: 28101405

20. Sourbron S, Ingrisch M, Siefert A, Reiser M, Herrmann K. Quantification of cerebral blood flow, cerebral blood volume, and blood-brain-barrier leakage with DCE-MRI. Magn Reson Med. 2009; 62: 205–17. https://doi.org/10.1002/mrm.22005 PMID: 19449435

21. Sarantopoulos A, Themelis G, Ntziachristos V. Imaging the bio-distribution of fluorescent probes using multispectral epi-illumination cryoslicing imaging. Mol Imaging Biol. 2011; 13: 874–85. https://doi.org/10.1007/s11307-010-0416-8 PMID: 20838910

22. Xie B, Tomaszewski MR, Neves A, Ros S, Hu DE, McGuire S, et al. Deep tissue photoacoustic computed tomography with a fast and compact laser system. Biomed Opt Express. 2017; 8: 112–23. https://doi.org/10.1364/BOE.8.000112 PMID: 28101405

23. Haedicke K, Brand C, Omar M, Ntziachristos V, Reiner T, Grimm J. Sonophore labeled RGD: a targeted contrast agent for optoacoustic imaging. Photoacoustics. 2017; 6: 1–8. https://doi.org/10.1016/j.pacs.2017.03.001 PMID: 28393018

24. Hudson SV, Huang JS, Yin W, Albeituni S, Rush J, Khanal A, et al. Targeted noninvasive imaging of EGFR-expressing orthotopic pancreatic cancer using multispectral optoacoustic tomography. Cancer Res. 2014; 74: 6271–9. https://doi.org/10.1158/0008-5472.CAN-14-1656 PMID: 25217521

25. Kniebling F, Neufert C, Hartmann A, Claussen J, Urich A, Egger C, et al. Multispectral Optoacoustic Tomography for Assessment of Crohn’s Disease Activity. N Engl J Med. 2017; 376: 1292–4. https://doi.org/10.1056/NEJMc1612455 PMID: 28355498

26. Haedicke K, Brand C, Omar M, Ntziachristos V, Reiner T, Grimm J. Sonophore labeled RGD: a targeted contrast agent for optoacoustic imaging. Photoacoustics. 2017; 6: 1–8. https://doi.org/10.1016/j.pacs.2017.03.001 PMID: 28393018

27. Kneiling F, Neufert C, Hartmann A, Claussen J, Urich A, Egger C, et al. Multispectral Optoacoustic Tomography for Assessment of Crohn’s Disease Activity. N Engl J Med. 2017; 376: 1292–4. https://doi.org/10.1056/NEJMc1612455 PMID: 28355498

28. Dima A, Ntziachristos V. In-vivo handheld optoacoustic tomography of the human thyroid. Photoacoustics. 2016; 4: 65–9. https://doi.org/10.1016/j.pacs.2016.05.003 PMID: 27766210

29. Gujrati V, Mishra A, Ntziachristos V. Molecular imaging probes for multi-spectral optoacoustic tomography. Chem Commun (Camb). 2017; 53: 4653–72.

30. Gibbs SL. Near infrared fluorescence for image-guided surgery. Quant Imaging Med Surg. 2012; 2: 177–87. https://doi.org/10.3978/j.sss.issn.2223-4292.2012.09.04 PMID: 23256079

31. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first-in-human results. Nat Med. 2011; 17: 1315–9. https://doi.org/10.1038/nm.2472 PMID: 21926976

32. Tummers QR, Hoogstins CE, Gaarenstroom KN, de Kroon CD, van Poelgeest MI, Vuyk J, et al. Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. Oncotarget. 2016; 7: 32144–55. https://doi.org/10.18632/oncotarget.8282 PMID: 27014973

33. Lee JH, Wang TD. Molecular endoscopy for targeted imaging in the digestive tract. Lancet Gastroenterol Hepatol. 2016; 1: 147–55. https://doi.org/10.1016/S2468-1253(16)30027-9 PMID: 28404071

34. Harlaar NJ, Koller M, de Jongh SJ, van Leeuwen BL, Hemmer PH, Kruijff S, et al. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. Lancet Gastroenterol Hepatol. 2016; 1: 283–90. https://doi.org/10.1016/S2468-1253(16)30082-6 PMID: 28404198

35. Martelli C, Lo Dico A, Diceglie C, Lucignani G, Ottobrini L. Optical imaging probes in oncology. Oncotarget. 2016; 7: 48753–87. https://doi.org/10.18632/oncotarget.9066 PMID: 27145373

36. Arrieta O, Garcia-Perez FO, Michel-Tello D, Ramirez-Tirado LA, Pitalua-Cortes Q, Cruz-Rico G, et al. Response assessment of 68Ga-DOTA-E-[c(RGDfK)]2 PET/CT for lung adenocarcinoma patients treated with nintedanib plus docetaxel. J Nucl Med. 2017.
38. Cui Y, Zhang C, Luo R, Liu H, Zhang Z, Xu T, et al. Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles. Int J Nanomedicine. 2016; 11: 5671–82. https://doi.org/10.2147/IJN.S115357 PMID: 27895477

39. Kazmierczak PM, Schneider M, Habereder T, Himer-Eppeneder H, Eschbach RS, Moser M, et al. αvβ3-Integrin-Targeted Magnetic Resonance Imaging for the Assessment of Early Antiangiogenic Therapy Effects in Orthotopic Breast Cancer Xenografts. Invest Radiol. 2016; 51: 746–55. https://doi.org/10.1097/RLI.0000000000000278 PMID: 27082316

40. Joseph J, Tomaszewski MR, Quiros-Gonzalez I, Weber J, Brunker J, Bohndiek SE. Evaluation of Precision in Optoacoustic Tomography for Preclinical Imaging in Living Subjects. J Nucl Med. 2017; 58: 807–14. https://doi.org/10.2967/jnumed.116.182311 PMID: 28126890

41. Chen H, Niu G, Wu H, Chen X. Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin alphavbeta3. Theranostics. 2016; 6: 78–92. https://doi.org/10.7150/thno.13242 PMID: 26722375

42. Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, et al. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther. 2006; 5: 3122–9. https://doi.org/10.1158/1535-7163.MCT-06-0356 PMID: 17172415